Merit E Cudkowicz

List of Publications by Year
in descending order

117 papers	9,091 citations	66343 42 h-index	45317 90 g-index
124 all docs	124 docs citations	124 times ranked	10338 citing authors

#	Article	IF	Citations
1	ALSUntangled #63: ketogenic diets. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2023, 24, 159-163.	1.7	3
2	Medical therapies for amyotrophic lateral sclerosis-related respiratory decline: an appraisal of needs, opportunities and obstacles. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 66-75.	1.7	1
3	Novel genetic variants in MAPT and alterations in tau phosphorylation in amyotrophic lateral sclerosis postâ€mortem motor cortex and cerebrospinal fluid. Brain Pathology, 2022, 32, e13035.	4.1	15
4	Targeting Tau Mitigates Mitochondrial Fragmentation and Oxidative Stress in Amyotrophic Lateral Sclerosis. Molecular Neurobiology, 2022, 59, 683-702.	4.0	18
5	Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis. Neurology, 2022, 98, .	1.1	51
6	A Phase 1 study of <scp>GDC</scp>â€0134, a dual leucine zipper kinase inhibitor, in <scp>ALS</scp>. Annals of Clinical and Translational Neurology, 2022, 9, 50-66.	3.7	20
7	A randomized <scp>placeboâ€controlled</scp> phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis. Muscle and Nerve, 2022, 65, 291-302.	2.2	41
8	Adaptive Platform Trials to Transform Amyotrophic Lateral Sclerosis Therapy Development. Annals of Neurology, 2022, 91, 165-175.	5.3	41
9	Phase <scp>2B</scp> randomized controlled trial of <scp>NP001</scp> in amyotrophic lateral sclerosis: Preâ€specified and post hoc analyses. Muscle and Nerve, 2022, 66, 39-49.	2.2	16
10	Answer ALS, a large-scale resource for sporadic and familial ALS combining clinical and multi-omics data from induced pluripotent cell lines. Nature Neuroscience, 2022, 25, 226-237.	14.8	66
11	Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trial. Neuro-Oncology Advances, 2022, 4, vdab186.	0.7	1
12	ALSUntangled #64: butyrates. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 638-643.	1.7	6
13	Regulatory Approval in ALS; When Is a Single Study Enough?. Annals of Neurology, 2022, 91, 737-739.	5.3	4
14	Survival analyses from the <scp>CENTAUR</scp> trial in amyotrophic lateral sclerosis: Evaluating the impact of treatment crossover on outcomes. Muscle and Nerve, 2022, 66, 136-141.	2.2	30
15	Effect of sodium phenylbutyrate/taurursodiol on tracheostomy/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: long-term results from the CENTAUR trial. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 871-875.	1.9	37
16	An expanded access protocol of <scp>RT001</scp> in amyotrophic lateral sclerosisâ€”Initial experience with a lipid peroxidation inhibitor. Muscle and Nerve, 2022, 66, 421-425.	2.2	10
17	Longâ€term survival of participants in the <scp>CENTAUR</scp> trial of sodium phenylbutyrateâ€taurursodiol in <scp>amyotrophic lateral sclerosis</scp>. Muscle and Nerve, 2021, 63, 31-39.	2.2	115
18	Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis. JAMA Neurology, 2021, 78, 186.	9.0	79

#	Article	IF	Citations
19	Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nature Reviews Neurology, 2021, 17, 104-118.	10.1	152
20	Ibudilast (MN-166) in amyotrophic lateral sclerosis- an open label, safety and pharmacodynamic trial. NeuroImage: Clinical, 2021, 30, 102672.	2.7	21
21	Regional prefrontal cortical atrophy predicts specific cognitive-behavioral symptoms in ALS-FTD. Brain Imaging and Behavior, 2021, 15, 2540-2551.	2.1	9
22	Noninvasive ventilation use by patients enrolled in VITALITY-ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 1-9.	1.7	0
23	Tocilizumab is safe and tolerable and reduces <scp>C</scp>â€reactive protein concentrations in the plasma and cerebrospinal fluid of <scp>ALS</scp> patients. Muscle and Nerve, 2021, 64, 309-320.	2.2	27
24	Genome-encoded cytoplasmic double-stranded RNAs, found in C9ORF72 ALS-FTD brain, propagate neuronal loss. Science Translational Medicine, 2021, 13, .	12.4	27
25	Gold Coast diagnostic criteria: Implications for <scp>ALS</scp> diagnosis and clinical trial enrollment. Muscle and Nerve, 2021, 64, 532-537.	2.2	16
26	Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 821-831.	10.2	9
27	Effects of mexiletine on hyperexcitability in sporadic amyotrophic lateral sclerosis: Preliminary findings from a small phase II randomized controlled trial. Muscle and Nerve, 2021, 63, 371-383.	2.2	13
28	Radicava/Edaravone Findings in Biomarkers From Amyotrophic Lateral Sclerosis (REFINE-ALS): Protocol and Study Design. Neurology: Clinical Practice, 2021, 11, e472-e479.	1.6	0
29	Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 15-23.	1.7	12
30	Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS. Muscle and Nerve, 2020, 62, 156-166.	2.2	60
31	Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntingtonâ€™s Disease Patientsâ€”A Randomized Phase 2 Clinical Trial. Journal of Clinical Medicine, 2020, 9, 3682.	2.4	15
32	Imaging Neurochemistry and Brain Structure Tracks Clinical Decline and Mechanisms of ALS in Patients. Frontiers in Neurology, 2020, 11, 590573.	2.4	16
33	Trial of Sodium Phenylbutyrateâ€“Taurursodiol for Amyotrophic Lateral Sclerosis. New England Journal of Medicine, 2020, 383, 919-930.	27.0	299
34	Phase 1â€“2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. New England Journal of Medicine, 2020, 383, 109-119.	27.0	354
35	ALS clinical research learning institutes (ALS-CRLI): empowering people with ALS to be research ambassadors. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 216-221.	1.7	5
36	Baseline Variables Associated with Functional Decline in 2CARE, A Randomized Clinical Trial in Huntingtonâ€™s Disease. Journal of Huntington's Disease, 2020, 9, 47-58.	1.9	0

#	Article	IF	Citations
37	Seven-Year Experience From the National Institute of Neurological Disorders and Strokeâ€“Supported Network for Excellence in Neuroscience Clinical Trials. JAMA Neurology, 2020, 77, 755.	9.0	6
38	Amyotrophic lateral sclerosis care and research in the United States during the <scp>COVID</scp>â€19 pandemic: Challenges and opportunities. Muscle and Nerve, 2020, 62, 182-186.	2.2	42
39	Preface: promoting research in PLS: current knowledge and future challenges. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 1-2.	1.7	6
40	ALS/SURV: a modification of the CAFS statistic. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 576-583.	1.7	2
41	Prospective natural history study of C9orf72 ALS clinical characteristics and biomarkers. Neurology, 2019, 93, e1605-e1617.	1.1	29
42	Stratification of amyotrophic lateral sclerosis patients: a crowdsourcing approach. Scientific Reports, 2019, 9, 690.	3.3	46
43	Nutritional counseling with or without mobile health technology: a randomized open-label standard-of-care-controlled trial in ALS. BMC Neurology, 2019, 19, 104.	1.8	13
44	A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 584-594.	1.7	29
45	Risk factors for suicidality in Huntington disease. Neurology, 2019, 92, e1643-e1651.	1.1	22
46	Cromolyn sodium delays disease onset and is neuroprotective in the SOD1G93A Mouse Model of amyotrophic lateral sclerosis. Scientific Reports, 2019, 9, 17728.	3.3	26
47	NurOwn, phase 2, randomized, clinical trial in patients with ALS. Neurology, 2019, 93, e2294-e2305.	1.1	95
48	Final Results of the RHAPSODY Trial: A Multiâ€Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3Aâ€APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke. Annals of Neurology, 2019, 85, 125-136.	5.3	113
49	A pilot trial of RNS60 in amyotrophic lateral sclerosis. Muscle and Nerve, 2019, 59, 303-308.	2.2	29
50	Mexiletine for muscle cramps in amyotrophic lateral sclerosis: A randomized, doubleâ€blind crossover trial. Muscle and Nerve, 2018, 58, 42-48.	2.2	38
51	Understanding the use of NIV in ALS: results of an international ALS specialist survey. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 331-341.	1.7	31
52	Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS. Neurology, 2018, 90, e565-e574.	1.1	99
53	VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristics. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 259-266.	1.7	21
54	An open label study of a novel immunosuppression intervention for the treatment of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 242-249.	1.7	35

#	Article	IF	Citations
55	Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron, 2018, 97, 1268-1283.e6.	8.1	517
56	Respiratory measures in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 321-330.	1.7	44
57	Imaging of glia activation in people with primary lateral sclerosis. NeuroImage: Clinical, 2018, 17, 347-353.	2.7	29
58	Urate levels predict survival in amyotrophic lateral sclerosis: Analysis of the expanded Pooled Resource Openâ€Access ALS clinical trials database. Muscle and Nerve, 2018, 57, 430-434.	2.2	39
59	A randomized controlled trial of resistance and endurance exercise in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 250-258.	1.7	44
60	Opinion and Special Articles: Challenges and opportunities in defining career identity in academic neurology. Neurology, 2018, 91, 670-672.	1.1	6
61	Pilot trial of inosine to elevate urate levels in amyotrophic lateral sclerosis. Annals of Clinical and Translational Neurology, 2018, 5, 1522-1533.	3.7	31
62	Expanded autologous regulatory T-lymphocyte infusions in ALS. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e465.	6.0	116
63	Initial Identification of a Blood-Based Chromosome Conformation Signature for Aiding in the Diagnosis of Amyotrophic Lateral Sclerosis. EBioMedicine, 2018, 33, 169-184.	6.1	17
64	Recruitment & retention program for the NeuroNEXT SMA Biomarker Study: Super Babies for SMA!. Contemporary Clinical Trials Communications, 2018, 11, 113-119.	1.1	11
65	Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. Journal of Clinical Investigation, 2018, 128, 3558-3567.	8.2	171
66	Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial. Neurotherapeutics, 2017, 14, 762-772.	4.4	73
67	Fixed dynamometry is more sensitive than vital capacity or ALS rating scale. Muscle and Nerve, 2017, 56, 710-715.	2.2	15
68	Defining SOD1 ALS natural history to guide therapeutic clinical trial design. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 99-105.	1.9	68
69	Developing multidisciplinary clinics for neuromuscular care and research. Muscle and Nerve, 2017, 56, 848-858.	2.2	38
70	Vitamin D levels are associated with gross motor function in amyotrophic lateral sclerosis. Muscle and Nerve, 2017, 56, 726-731.	2.2	22
71	Natural history of infantileâ€onset spinal muscular atrophy. Annals of Neurology, 2017, 82, 883-891.	5.3	276
72	Serum urate at trial entry and ALS progression in EMPOWER. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 120-125.	1.7	20

#	Article	IF	Citations
73	Analysis of Participant Withdrawal in Huntington Disease Clinical Trials. Journal of Huntington's Disease, 2017, 6, 149-156.	1.9	0
74	Functional Decline is Associated with Hopelessness in Amyotrophic Lateral Sclerosis (ALS). Journal of Neurology & Neurophysiology, 2017, 08, .	0.1	17
75	The Role of Environmental Toxins in Amyotrophic Lateral Sclerosis Risk. JAMA Neurology, 2016, 73, 779.	9.0	5
76	Selecting Patients for Intra-Arterial Therapy in the Context of a Clinical Trial for Neuroprotection. Stroke, 2016, 47, 2979-2985.	2.0	20
77	Quantitative strength testing in ALS clinical trials. Neurology, 2016, 87, 617-624.	1.1	37
78	Transplantation of spinal cordâ€“derived neural stem cells for ALS. Neurology, 2016, 87, 392-400.	1.1	127
79	Race/ethnicity, socioeconomic status, and ALS mortality in the United States. Neurology, 2016, 87, 2300-2308.	1.1	37
80	Glial activation colocalizes with structural abnormalities in amyotrophic lateral sclerosis. Neurology, 2016, 87, 2554-2561.	1.1	83
81	Primary Lateral Sclerosis and Early Upper Motor Neuron Disease. Journal of Clinical Neuromuscular Disease, 2016, 17, 99-105.	0.7	17
82	How common are ALS plateaus and reversals?. Neurology, 2016, 86, 808-812.	1.1	78
83	Job-related formaldehyde exposure and ALS mortality in the USA: TableÂ1. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 786-788.	1.9	30
84	A randomized trial of mexiletine in ALS. Neurology, 2016, 86, 1474-1481.	1.1	72
85	Preclinical rodent toxicity studies for long term use of ceftriaxone. Toxicology Reports, 2015, 2, 1396-1403.	3.3	7
86	Reply. Muscle and Nerve, 2015, 52, 691-691.	2.2	2
87	Preâ€morbid type 2 diabetes mellitus is not a prognostic factor in amyotrophic lateral sclerosis. Muscle and Nerve, 2015, 52, 339-343.	2.2	25
88	Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: Assessed with [11C]-PBR28. NeuroImage: Clinical, 2015, 7, 409-414.	2.7	176
89	Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression. Nature Biotechnology, 2015, 33, 51-57.	17.5	178
90	Randomized phase 2 trial of NP001, a novel immune regulator. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e100.	6.0	83

#	Article	IF	Citations
91	Cortical Hyperexcitability in Amyotrophic Lateral Sclerosis. JAMA Neurology, 2015, 72, 1235.	9.0	11
92	ISDN2014_0028: REMOVED: Targeting miRâ€155 restores dysfunctional microglia and ameliorates disease in the SOD1 model of ALS. International Journal of Developmental Neuroscience, 2015, 47, 5-5.	1.6	1
93	Neuroprotective agents target molecular mechanisms of disease in ALS. Drug Discovery Today, 2015, 20, 65-75.	6.4	30
94	Safety, Pharmacokinetic, and Functional Effects of the Nogo-A Monoclonal Antibody in Amyotrophic Lateral Sclerosis: A Randomized, First-In-Human Clinical Trial. PLoS ONE, 2014, 9, e97803.	2.5	45
95	The PRO-ACT database. Neurology, 2014, 83, 1719-1725.	1.1	222
96	Inosine to Increase Serum and Cerebrospinal Fluid Urate in Parkinson Disease. JAMA Neurology, 2014, 71, 141.	9.0	211
97	Locked in, but not out?. Neurology, 2014, 82, 1852-1853.	1.1	17
98	Outcome measures in amyotrophic lateral sclerosis clinical trials. Clinical Investigation, 2014, 4, 605-618.	0.0	50
99	Intrinsic Membrane Hyperexcitability of Amyotrophic Lateral Sclerosis Patient-Derived Motor Neurons. Cell Reports, 2014, 7, 1-11.	6.4	583
100	Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2014, 13, 1083-1091.	10.2	187
101	Discovery of a Biomarker and Lead Small Molecules to Target r(GGGGCC)-Associated Defects in c9FTD/ALS. Neuron, 2014, 83, 1043-1050.	8.1	289
102	Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet, The, 2014, 383, 2065-2072.	13.7	233
103	Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurology, The, 2013, 12, 1059-1067.	10.2	216
104	The Combined Assessment of Function and Survival (CAFS): A new endpoint for ALS clinical trials. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 162-168.	1.7	88
105	The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nature Medicine, 2011, 17, 1652-1656.	30.7	166
106	A futility study of minocycline in Huntington's disease. Movement Disorders, 2010, 25, 2219-2224.	3.9	79
107	Toward more efficient clinical trials for amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 259-265.	2.1	77
108	Phase 2 study of sodium phenylbutyrate in ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 99-106.	2.1	135

#	Article	IF	Citations
109	Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis. Muscle and Nerve, 2008, 38, 837-844.	2.2	104
110	Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. Journal of Neurochemistry, 2006, 96, 908-908.	3.9	2
111	Trial of celecoxib in amyotrophic lateral sclerosis. Annals of Neurology, 2006, 60, 22-31.	5.3	276
112	Maximum voluntary isometric contraction (MVIC). Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2004, 5, 84-85.	1.2	11
113	Measures and markers in Amyotrophic Lateral Sclerosis. NeuroRx, 2004, 1, 273-283.	6.0	63
114	Measures and markers in Amyotrophic Lateral Sclerosis. Neurotherapeutics, 2004, 1, 273-283.	4.4	0
115	Dynamic markers of altered gait rhythm in amyotrophic lateral sclerosis. Journal of Applied Physiology, 2000, 88, 2045-2053.	2.5	400
116	Gait variability and basal ganglia disorders: Strideâ€toâ€stride variations of gait cycle timing in parkinson's disease and Huntington's disease. Movement Disorders, 1998, 13, 428-437.	3.9	752
117	Identification of Therapeutic Targets for Amyotrophic Lateral Sclerosis Using PandaOmics â€“ An AI-Enabled Biological Target Discovery Platform. Frontiers in Aging Neuroscience, 0, 14, .	3.4	32